In conclusion, our study raised the hypothesis that DPP4-inhibitors might aggravate diabetic retinopathy by increasing vascular permeability through the SDF-1α/CXCR4 axis, followed by Src activation and phosphorylation of VE-cadherin. Here, CXCR4 is linked to diabetic retinopathy.